Study of Relma-cel followed by Tislelizumab to treat relapsed or refractory large B-cell lymphoma in the central nervous system

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Relma-cel followed by Tislelizumab in treating people with relapsed or refractory central nervous system large B-cell lymphoma CNSL. The study also looks at how the body processes Relma-cel. This phase 2 trial includes patients whose lymphoma has returned or not responded after prior treatments. Participants will receive an infusion of Relma-cel, then start Tislelizumab treatment 200 mg given intravenously every 4 weeks beginning 35 days after the infusion and continuing for 12 months. Brutons tyrosine kinase BTK inhibitors may be added if needed. The study focuses on one treatment group receiving this combination. During the study, participants will be monitored for drug safety, disease status, survival, and how Relma-cel behaves in the body. The main measure is the complete response rate three months after the Relma-cel infusion. Secondary outcomes include progression-free survival, overall survival, and objective remission rate assessed up to two years post-infusion. Follow-up will continue for four years to track long-term results.

Relma-cel Followed by Tislelizumab for the Treatment of Relapsed/Refractory CNS Large B-Cell Lymphoma